スポンサーリンク
東北大学病院 血液･免疫科 | 論文
- Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR
- Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia : the JALSG AML95 study
- Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan : a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group
- Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group
- Use of Octreotide in the Management of Severe Duodenal Bleeding after Unrelated-Donor Bone Marrow Transplantation
- Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer
- Interlaboratory Comparison of Quantitative RT-PCR Based Detection for Minimal Residual Disease in Leukemias : A Standardization Approach in Japan
- Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
- Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia
- Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
- Characterization of the light chain-restricted clonal B cells in peripheral blood of HCV-positive patients
- Periostin and bone marrow fibrosis
- Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes
- Management of infection in patients with acute leukemia during chemotherapy in Japan : questionnaire analysis by the Japan Adult Leukemia Study Group
- A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
- Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis
- Acquired hemophilia A with sigmoid colon cancer : successful treatment with rituximab followed by sigmoidectomy
- A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma : β2-microglobulin associated with time to progression
- Dose Modification of Imatinib by Monitoring the Level of BCR-ABL Transcript in Chronic Myelogenous Leukemia